The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Ahmed Sayed - One of the best experts on this subject based on the ideXlab platform.
-
extended letrozole regimen versus clomiphene citrate for Superovulation in patients with unexplained infertility undergoing intrauterine insemination a randomized controlled trial
Reproductive Biology and Endocrinology, 2011Co-Authors: Usama M Fouda, Ahmed SayedAbstract:Background: The aim of this randomized controlled trial was to compare the efficacy of extended letrozole regimen with clomiphene citrate in women with unexplained infertility undergoing Superovulation and intrauterine insemination (IUI). Methods: Two hundred and fourteen patients with unexplained infertility were randomized into two equal groups using computer generated list and were treated by either letrozole 2.5 mg/day from cycle day 1 to 9 (extended letrozole group, 211 cycles) or clomiphene citrate 100 mg/day from cycle day 3 to 7 (clomiphene citrate group,210 cycles). Intrauterine insemination was performed 36 to 40 hours after HCG administration. Results: Both groups were comparable with regard to number of mature follicles (2.24 +/- 0.80 Vs 2.13 +/- 0.76) and the day of HCG administration. Serum estradiol was significantly greater in clomiphene citrate group (356 +/151 Vs 822 +/- 302 pg/ml, P = < 0.001) and the endometrial thickness was significantly greater in extended letrozole group (9.10 +/- 1.84 Vs 8.18 +/- 1.93 mm, P = < 0.001).The pregnancy rate per cycle and cumulative pregnancy rate were significantly greater in extended letrozole group (18.96% Vs 11.43% and 37.73% Vs 22.86%, respectively). Conclusion: The extended letrozole regimen had a superior efficacy as compared with clomiphene citrate in patients of unexplained infertility undergoing Superovulation and IUI. Trial registration: ClinicalTrials.gov, NCT01232075
-
extended letrozole regimen versus clomiphene citrate for Superovulation in patients with unexplained infertility undergoing intrauterine insemination a randomized controlled trial
Reproductive Biology and Endocrinology, 2011Co-Authors: Usama M Fouda, Ahmed SayedAbstract:The aim of this randomized controlled trial was to compare the efficacy of extended letrozole regimen with clomiphene citrate in women with unexplained infertility undergoing Superovulation and intrauterine insemination (IUI). Two hundred and fourteen patients with unexplained infertility were randomized into two equal groups using computer generated list and were treated by either letrozole 2.5 mg/day from cycle day 1 to 9 (extended letrozole group, 211 cycles) or clomiphene citrate 100 mg/day from cycle day 3 to 7 (clomiphene citrate group,210 cycles). Intrauterine insemination was performed 36 to 40 hours after HCG administration. Both groups were comparable with regard to number of mature follicles (2.24 +/- 0.80 Vs 2.13 +/- 0.76) and the day of HCG administration. Serum estradiol was significantly greater in clomiphene citrate group (356 +/- 151 Vs 822 +/- 302 pg/ml, P = < 0.001) and the endometrial thickness was significantly greater in extended letrozole group (9.10 +/- 1.84 Vs 8.18 +/- 1.93 mm, P = < 0.001).The pregnancy rate per cycle and cumulative pregnancy rate were significantly greater in extended letrozole group (18.96% Vs 11.43% and 37.73% Vs 22.86%, respectively). The extended letrozole regimen had a superior efficacy as compared with clomiphene citrate in patients of unexplained infertility undergoing Superovulation and IUI. ClinicalTrials.gov, NCT01232075
Necdet Demir - One of the best experts on this subject based on the ideXlab platform.
-
Superovulation alters embryonic poly a binding protein epab and poly a binding protein cytoplasmic 1 pabpc1 gene expression in mouse oocytes and early embryos
Reproduction Fertility and Development, 2016Co-Authors: Saffet Ozturk, Berna Sozen, Aylin Yabaucar, Derya Mutlu, Necdet DemirAbstract:Embryonic poly(A)-binding protein (EPAB) and poly(A)-binding protein, cytoplasmic 1 (PABPC1) play critical roles in translational regulation of stored maternal mRNAs required for proper oocyte maturation and early embryo development in mammals. Superovulation is a commonly used technique to obtain a great number of oocytes in the same developmental stages in assisted reproductive technology (ART) and in clinical or experimental animal studies. Previous studies have convincingly indicated that Superovulation alone can cause impaired oocyte maturation, delayed embryo development, decreased implantation rate and increased postimplantation loss. Although how Superovulation results in these disturbances has not been clearly addressed yet, putative changes in genes related to oocyte and early embryo development seem to be potential risk factors. Thus, the aim of the present study was to determine the effect of Superovulation on Epab and Pabpc1 gene expression. To this end, low- (5IU) and high-dose (10IU) pregnant mare's serum gonadotropin (PMSG) and human chorionic gonadotrophin (hCG) were administered to female mice to induce Superovulation, with naturally cycling female mice serving as controls. Epab and Pabpc1 gene expression in germinal vesicle (GV) stage oocytes, MII oocytes and 1- and 2-cell embryos collected from each group were quantified using quantitative reverse transcription-polymerase chain reaction. Superovulation with low or high doses of gonadotropins significantly altered Epab and Pabpc1 mRNA levels in GV oocytes, MII oocytes and 1- and 2-cell embryos compared with their respective controls (P<0.05). These changes most likely lead to variations in expression of EPAB- and PABPC1-regulated genes, which may adversely influence the quality of oocytes and early embryos retrieved using Superovulation.
Usama M Fouda - One of the best experts on this subject based on the ideXlab platform.
-
extended letrozole regimen versus clomiphene citrate for Superovulation in patients with unexplained infertility undergoing intrauterine insemination a randomized controlled trial
Reproductive Biology and Endocrinology, 2011Co-Authors: Usama M Fouda, Ahmed SayedAbstract:Background: The aim of this randomized controlled trial was to compare the efficacy of extended letrozole regimen with clomiphene citrate in women with unexplained infertility undergoing Superovulation and intrauterine insemination (IUI). Methods: Two hundred and fourteen patients with unexplained infertility were randomized into two equal groups using computer generated list and were treated by either letrozole 2.5 mg/day from cycle day 1 to 9 (extended letrozole group, 211 cycles) or clomiphene citrate 100 mg/day from cycle day 3 to 7 (clomiphene citrate group,210 cycles). Intrauterine insemination was performed 36 to 40 hours after HCG administration. Results: Both groups were comparable with regard to number of mature follicles (2.24 +/- 0.80 Vs 2.13 +/- 0.76) and the day of HCG administration. Serum estradiol was significantly greater in clomiphene citrate group (356 +/151 Vs 822 +/- 302 pg/ml, P = < 0.001) and the endometrial thickness was significantly greater in extended letrozole group (9.10 +/- 1.84 Vs 8.18 +/- 1.93 mm, P = < 0.001).The pregnancy rate per cycle and cumulative pregnancy rate were significantly greater in extended letrozole group (18.96% Vs 11.43% and 37.73% Vs 22.86%, respectively). Conclusion: The extended letrozole regimen had a superior efficacy as compared with clomiphene citrate in patients of unexplained infertility undergoing Superovulation and IUI. Trial registration: ClinicalTrials.gov, NCT01232075
-
extended letrozole regimen versus clomiphene citrate for Superovulation in patients with unexplained infertility undergoing intrauterine insemination a randomized controlled trial
Reproductive Biology and Endocrinology, 2011Co-Authors: Usama M Fouda, Ahmed SayedAbstract:The aim of this randomized controlled trial was to compare the efficacy of extended letrozole regimen with clomiphene citrate in women with unexplained infertility undergoing Superovulation and intrauterine insemination (IUI). Two hundred and fourteen patients with unexplained infertility were randomized into two equal groups using computer generated list and were treated by either letrozole 2.5 mg/day from cycle day 1 to 9 (extended letrozole group, 211 cycles) or clomiphene citrate 100 mg/day from cycle day 3 to 7 (clomiphene citrate group,210 cycles). Intrauterine insemination was performed 36 to 40 hours after HCG administration. Both groups were comparable with regard to number of mature follicles (2.24 +/- 0.80 Vs 2.13 +/- 0.76) and the day of HCG administration. Serum estradiol was significantly greater in clomiphene citrate group (356 +/- 151 Vs 822 +/- 302 pg/ml, P = < 0.001) and the endometrial thickness was significantly greater in extended letrozole group (9.10 +/- 1.84 Vs 8.18 +/- 1.93 mm, P = < 0.001).The pregnancy rate per cycle and cumulative pregnancy rate were significantly greater in extended letrozole group (18.96% Vs 11.43% and 37.73% Vs 22.86%, respectively). The extended letrozole regimen had a superior efficacy as compared with clomiphene citrate in patients of unexplained infertility undergoing Superovulation and IUI. ClinicalTrials.gov, NCT01232075
Saffet Ozturk - One of the best experts on this subject based on the ideXlab platform.
-
Superovulation alters embryonic poly a binding protein epab and poly a binding protein cytoplasmic 1 pabpc1 gene expression in mouse oocytes and early embryos
Reproduction Fertility and Development, 2016Co-Authors: Saffet Ozturk, Berna Sozen, Aylin Yabaucar, Derya Mutlu, Necdet DemirAbstract:Embryonic poly(A)-binding protein (EPAB) and poly(A)-binding protein, cytoplasmic 1 (PABPC1) play critical roles in translational regulation of stored maternal mRNAs required for proper oocyte maturation and early embryo development in mammals. Superovulation is a commonly used technique to obtain a great number of oocytes in the same developmental stages in assisted reproductive technology (ART) and in clinical or experimental animal studies. Previous studies have convincingly indicated that Superovulation alone can cause impaired oocyte maturation, delayed embryo development, decreased implantation rate and increased postimplantation loss. Although how Superovulation results in these disturbances has not been clearly addressed yet, putative changes in genes related to oocyte and early embryo development seem to be potential risk factors. Thus, the aim of the present study was to determine the effect of Superovulation on Epab and Pabpc1 gene expression. To this end, low- (5IU) and high-dose (10IU) pregnant mare's serum gonadotropin (PMSG) and human chorionic gonadotrophin (hCG) were administered to female mice to induce Superovulation, with naturally cycling female mice serving as controls. Epab and Pabpc1 gene expression in germinal vesicle (GV) stage oocytes, MII oocytes and 1- and 2-cell embryos collected from each group were quantified using quantitative reverse transcription-polymerase chain reaction. Superovulation with low or high doses of gonadotropins significantly altered Epab and Pabpc1 mRNA levels in GV oocytes, MII oocytes and 1- and 2-cell embryos compared with their respective controls (P<0.05). These changes most likely lead to variations in expression of EPAB- and PABPC1-regulated genes, which may adversely influence the quality of oocytes and early embryos retrieved using Superovulation.
Togas Tulandi - One of the best experts on this subject based on the ideXlab platform.
-
a randomized trial of letrozole versus clomiphene citrate in women undergoing Superovulation
Fertility and Sterility, 2004Co-Authors: Haya Alfozan, Seang Lin Tan, Maha Alkhadouri, Togas TulandiAbstract:Objective To compare the effects of the aromatase inhibitor letrozole (7.5 mg) and clomiphene citrate (CC; 100 mg) in women undergoing Superovulation and IUI. Design Prospective randomized trial. Setting University teaching hospital. Patient(s) We studied a total of 238 cycles of Superovulation and IUI in women with idiopathic infertility. Interventions Patients were randomized into treatment with 7.5 mg of letrozole daily (74 patients, 115 cycles) or 100 mg of CC daily (80 patients, 123 cycles). Main outcome measure(s) Number of follicles, endometrial thickness, pregnancy rate, and miscarriage rate. Result(s) The mean age, parity, and duration of infertility in both groups of patients were similar. There was no significant difference between the total number of developing follicles in the letrozole (5.7 ± 3.7) and in the CC groups (4.8 ± 2.5). The number of follicles of ≥14 mm and of >18 mm were 2.1 ± 1.2 and 1.4 ± 0.7 in the letrozole group, and 1.7 ± 0.9 and 1.1 ± 0.5 in the CC group, respectively. No difference was found in the endometrial thickness between the two groups (7.1 ± 0.2 mm in the letrozole group, 8.2 ± 5.9 mm in the CC group). The pregnancy rate per cycle was 11.5 % in the letrozole group and 8.9 % in the CC group. Four of the 11 pregnancies in the CC group resulted in a miscarriage (36.6 % ). Conclusion(s) Superovulation and IUI with letrozole and CC are associated with similar pregnancy rates, but the miscarriage rate is higher with CC. The ideal dose of letrozole remains unknown and further study is needed.
-
randomized controlled trial of Superovulation and insemination for infertility associated with minimal or mild endometriosis
Fertility and Sterility, 1997Co-Authors: Ian S Tummon, Linda J Asher, James S B Martin, Togas TulandiAbstract:Objective: To evaluate the efficacy of Superovulation and IUI versus no treatment for infertility associated with minimal or mild endometriosis. Design: Randomized trial. Setting(s): London Health Sciences Centre, University Campus, The University of Western Ontario, London, Ontario; and Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada. Patient(s): Three hundred eleven cycles in 103 couples in whom minimal or mild endometriosis was the sole identified subfertility factor. Intervention(s): Superovulation with FSH and IUI. Main Outcome Measure(s): Live birth. Result(s): Live birth followed 14 of 127 (11%) Superovulation and IUI cycles and 4 of 184 (2%) no-treatment cycles. The odds ratio was 5.6 (95% confidence interval 1.8 to 17.4) in favor of Superovulation and IUI. Conclusion(s): Treatment with Superovulation and IUI was associated with superior outcome both by crude live-birth rates and proportional hazard analysis.
